167 related articles for article (PubMed ID: 34174268)
21. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in advanced non-small-cell lung cancer with
Liu F; Yuan X; Jiang J; Chu Q
Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
[TBL] [Abstract][Full Text] [Related]
23. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
25. T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Kamimaki C; Kobayashi N; Hirata M; Somekawa K; Fukuda N; Kubo S; Katakura S; Teranishi S; Watanabe K; Horita N; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2021 Jun; 12(11):1726-1734. PubMed ID: 33943031
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
28. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
[TBL] [Abstract][Full Text] [Related]
29. Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer.
Icht O; Domachevsky L; Groshar D; Dudnik E; Rotem O; Allen AM; Peled N; Reinhorn D; Jacobi O; Shochat T; Bernstine H; Zer A
Asia Pac J Clin Oncol; 2021 Apr; 17(2):e125-e131. PubMed ID: 32762128
[TBL] [Abstract][Full Text] [Related]
30. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
31. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
32. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
34. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
Ku BM; Kim Y; Lee KY; Kim SY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2021 Apr; 51(4):956-964. PubMed ID: 33506525
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Oh MS; Guzner A; Wainwright DA; Mohindra NA; Chae YK; Behdad A; Villaflor VM
Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
[TBL] [Abstract][Full Text] [Related]
37.
Bredon M; Danne C; Pham HP; Ruffié P; Bessede A; Rolhion N; Creusot L; Brot L; Alonso I; Langella P; Derosa L; Cortot AB; Routy B; Zitvogel L; Segata N; Sokol H
Oncoimmunology; 2024; 13(1):2374954. PubMed ID: 38957477
[TBL] [Abstract][Full Text] [Related]
38. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
[TBL] [Abstract][Full Text] [Related]
40. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]